 - Results Demonstrate KD033 was Well Tolerated in All Patients through Initial Dose Cohorts, Allowing for Continuation of Dose Escalation - NEW YORK, NY ACCESSWIRE May 19, 2021 Kadmon Holdings, Inc. NASDAQ:KDMN today announced initial safety data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1IL-15 fusion protein, in patients with metastatic or locally advanced solid tumors. The data will be presented at the 2021 American Society of Clinical Oncology ASCO Annual Meeting taking place June 4 - 8, 2021. 